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Introduction
Chronic rhinosinusitis (CRS) affects 11% of the European popula-
tion and is associated with a significant socio-economic burden 
(1,2). CRS with and without nasal polyps are the main constitu-
ent disease entities with each having different pathophysio-
logical mechanisms or endotypes underlying the disease (3). 
Evidence-based treatment guidelines (EPOS) provide guidance 
to physicians for the management of CRS aiming at achieving or 
maintaining clinical control (4). The cornerstone of CRS treatment 
is prolonged anti-inflammatory treatment in combination with 
Functional Endoscopic Sinus Surgery (FESS) in case of failure of 
medical treatment. Despite currently available treatment mo-
dalities for CRS, including sinus surgery, up to 40% of patients 
still suffer from uncontrolled disease (5). Few studies so far have 
evaluated the burden of uncontrolled CRS in real life using the 
EPOS criteria for CRS disease control (5,6).
Uncontrolled upper airway disease might be attributed to 
disease-, treatment-, diagnosis- and patient-related factors 
(7). The relative importance of these factors still needs to be 
determined but it has been suggested that active participation 
of patients in the management of their disease may reduce the 
burden of uncontrolled disease through better adherence and 
personalized care (8,9). Mobile health technology has the poten-
tial to increase patient participation via self-management and 
education. Recently, education and personalized messages were 
identified in market research by app developers as most effec-
tive in changing patient behavior and are easy to implement (10). 
More challenging, but still having a high impact are app features 
that improve the communication with the healthcare provider 
(10). The success of future mobile (m)Health tools likely depends 
on the inclusion of those features that are lacking in most cur-
rently available apps for chronic upper airway diseases.
For example, MASK-rhinitis is a pioneering project allowing aller-
gic rhinitis patients to track their nasal, ocular or lung symptoms 
and share it with their health care provider (11,12). First results 
demonstrated its utility to phenotype patients with allergic rhi-
nitis (AR) and to evaluate the impact of allergic rhinitis on work 
productivity (13,14). Recently, the use of a visual analogue scale 
(VAS) on smartphone screens was validated to assess AR control 
(15). Follow-up studies are needed to demonstrate its utility in 
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improving disease control and adherence to treatment by the 
use of the app. Currently, different mobile apps related to sinus 
disease are available but none were developed by medical ex-
perts dealing with CRS. EUFOREA started a program to increase 
patient participation and empowerment in CRS, encouraging 
them to become active players in the integrated care pathway 
(16). This approach fully matches the concept of precision medi-
cine, for which participation of the patient is one of the 4 key pil-
lars (9,17). mySinusitisCoach has been developed in collaboration 
with the EUFOREA network of Rhinology experts, and different 
national and international bodies representing patients, primary 
care physicians, pharmacists and the eHealth community. This 
manuscript describes the developmental process, the different 
functionalities and the expected benefits of the app. We here 
aim to inform the Rhinology community about the unique ap-
proach used to design, develop and implement the app, which 
might serve as a state-of-the-art example for other projects.
Identifying the needs in CRS management
The needs of patients with CRS vary depending on the phase of 
their disease severity, experience and geographical distribution. 
It is assumed that patients with upper airway symptoms rely 
on self-medication and/or over-the-counter treatment to deal 
with the first symptoms of rhinosinusitis. Early detection of CRS 
is warranted to avoid delay in presentation to the primary care 
physician or ENT specialist. An integrated approach aligning 
different health care providers dealing with CRS is needed to 
deliver a uniform message to the patient (9). While newly diag-
nosed patients need reliable information about their disease 
and treatment options, patients with established or uncontrol-
led disease also require closer follow-up of their symptoms and 
disease control. Additionally, patients undergoing surgery will 
benefit from intensified monitoring of their symptoms. From the 
research perspective, there is a need to validate findings from 
clinical studies with real life data to guarantee applicability at 
the population level (18).
Implementation of supported self-management 
into clinical practice in CRS 
Treatment algorithms have been developed and presented 
in EPOS guidelines (4). From the patient’s perspective, poor 
adherence to treatment, incorrect use of treatment and limited 
knowledge about CRS and the treatment options might hamper 
their path to maintain or achieve optimal disease control (19–21). 
A blended health care approach is needed where the patient 
is well informed about the treatment options by the physician, 
in accordance with the guidelines, allowing the patient to 
understand the rationale of a treatment decision. Mobile health 
tools are aimed at supporting this process and allow disease 
monitoring over time, which contributes to supported self-
management of the disease.
Figure 1. Multi-stakeholder approach from design to implementation.
EFA: European Federation of Allergy and Airways Diseases Patients’ 
Associations, CEBAM: Belgian Centre for Evidence-Based Medicine, 
Domus Medica: Belgian Association of Primary Care Physicians, EAACI: 
European Academy of Allergy and Clinical Immunology, IPCRG: 
International Primary Care Group, APB: Association of Pharmacists in 
Belgium, PGEU: Pharmaceutical Group of the European Union.
Development of mySinusitisCoach: a multi-stake-
holder approach from design to implementation
EUFOREA aimed at consulting all relevant stakeholders early 
on during the process of design and development of mySinu-
sitisCoach. Patient-focused group meetings were organized in 
different countries throughout Europe to identify the patients’ 
needs and their perspective on new developments in the field 
of mobile health technology. In addition, national as well as 
international representatives of patient organizations (EFA), 
associations of primary care physicians (Domus Medica, IPCRG), 
associations of community pharmacists (Association of Phar-
macists in Belgium or APB and Pharmaceutical Group of the EU 
or PGEU) and E-Health community have provided feedback on 
design and development of mySinusitisCoach (Figure 1). This ap-
proach creates a unique European platform for dissemination of 
mySinusitisCoach and for implementation into clinical practice.
mySinusitisCoach: availability and data protection
The system has been initially deployed in three countries (Bel-
gium, The Netherlands and United Kingdom) and is available in 
two languages (Dutch and English). The app can be downloaded 
for free from the app stores (for iPhone: App Store, for smart-
phones that run on Android: Google Play). mySinusitisCoach has 
been registered as a class I medical device. Data aggregated in 
an anonymized way through mySinusitisCoach are stored on 
a private, secured server (ISO 27001 certified) for '15 years. A 
penetration test for the backend website of mySinusitisCoach 
is scheduled for 2018. Geolocalized data is only stored after ex-
plicit consent by the app user. The data are owned by EUFOREA. 
The Terms of Use allow the use of anonymized data for research 
purposes.
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Sinusitis Diary
The Sinusitis Diary is a simple tool to monitor rhinosinusitis 
symptoms and their impact on lower airway symptoms, sleep 
quality and work or daily life. This tool relies on a visual analogue 
scale, allowing the patient to score how bothersome a particular 
symptom is for him/her on a particular day. A similar system 
has been used and validated in the past to monitor allergy 
symptoms (15,22). The questions of the Sinusitis Diary are listed 
in Table 1. Questions with a previous VAS≤2 (e.g. result of the 
day before) were dropped from the Diary for 1 week to avoid an 
overload of questions that might be irrelevant for the patient at 
that time. 
In addition to rhinosinusitis symptoms, medication use is recor-
ded as a last item of the Diary. A weekly reminder to complete 
the Diary is activated in the app. This can be switched off/on 
and the time point can be chosen according to the patients’ 
preference.
Feedback to the patient
Upon completion of the Sinusitis Diary, the patient receives 
feedback about the level of control of his/her global rhinosinusi-
tis symptoms: well controlled (VAS≤2), partly controlled (VAS>2 
and VAS≤5), uncontrolled (VAS>5) (5). The results of the specific 
symptoms over time are visualized when rotating the screen 
of the mobile device into landscape mode. A patient who has 
uncontrolled disease for a prolonged time receives the following 
notifications: 
• After 1 week: ‘Your rhinosinusitis symptoms are uncontrol-
led. Did you  properly rinse your nose with saline?’
Monitoring disease control
Profile of the patient
Demographic characteristics (year of birth, gender, country, lan-
guage, smoking status), presence of co-morbidities (AR, asthma, 
COPD), disease-related factors (duration of symptoms, presence 
of nasal polyps, previous surgery) are recorded in the ‘Profile’ 
menu by the patient themselves. Country-specific medication 
lists for nasal, lung or eye symptoms are available from the ‘Pro-
file’ menu and allow patients to indicate their medication use, 
for which compliance can be recorded after filling the Diary.
Figure 2. Key functionalities of mySinusitisCoach.
Figure 3. Patient empowerment through feedback to the patient and the 
physician.
Figure 4. Patient empowerment via patient education.
VAS for Question
Global sinusitis symptoms
How much are your global sinusitis 
symptoms bothering you today?
Facial pain or headache
How much is facial pain or pressure at 
the forehead, head or eyes bothering you 
today?
Smell impairment
How much is loss of or reduced smell 
bothering you today?
Nasal Blockage
How much is nasal blockage bothering 
you today?
Nasal secretions
How much are your nasal secretions 
bothering you today?
Post-nasal drip
How much are nasal secretions dripping 
into the throat bothering you today?
Lower airway symptoms
How much is shortness of breath or 
wheezing bothering you today?
Impact on sleep quality
How much are your sinusitis symptoms 
affecting your sleep quality?
Impact on work and daily 
life
How much are your sinusitis symptoms 
affecting your work or daily activities 
today?
Table 1. Sinusitis Diary questions.
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• After 2 weeks: ‘Your rhinosinusitis symptoms are uncontrol-
led for 1 week. Did you properly take your medication?’
• After 3 weeks: ‘Your sinusitis symptoms are uncontrolled 
for 2 weeks. Uncontrolled sinus disease is seen in 40% of 
patients with chronic rhinosinusitis who were prescribed 
nasal sprays and have had sinus surgery. The reasons for 
that might be due to exposure to air pollution or allergens, 
other airway diseases, medication that is inefficiently redu-
cing the ongoing inflammation or not taking adequately 
your medication.’
• After 4 weeks: ‘Your rhinosinusitis symptoms are uncontrol-
led for 4 weeks. You may consider visiting your GP or ENT 
doctor to discuss your symptoms and check your treat-
ment.’ 
Feedback to the physician
During patient consultation, the data on the level of disease 
control, VAS of specific symptoms and use of medication can be 
visualized on any PC with internet connection. The link ‘www.
my-sinusitis-coach.com/data’ contains a QR code that can be 
scanned by the patient with his/her smartphone. At that time, 
the patient authorizes visualization of his/her data on the PC. 
Scanning allows the physician to identify the specific patient, to 
evaluate disease control and medication use; and discuss this in-
formation with the patient to determine or adapt CRS treatment 
for the following period.
Measuring quality of life
SNOT-22 questionnaire
The SinoNasal Outcome Test (SNOT)-22 questionnaire is widely 
used and validated to assess quality of life in CRS patients, to 
evaluate treatment effectiveness or to identify patients eligible 
for sinus surgery (23–26). This questionnaire has been included in 
the app as an optional questionnaire to complete monthly.
EQ-5D-5L questionnaire
The EuroQol-5Dimension-5Level (EQ-5D-5L) generic question-
Figure 5. Expected benefits of mySinusitiscoach for the different stake-
holders.
naire is used to assess the general health-related quality of life 
of chronically ill patients (27). Five specific dimensions of the pa-
tients’ health are scored: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Such generic questionnaire 
allows comparison of the patients’ overall health across different 
medical conditions. Similar to the SNOT-22 questionnaire, the 
EQ-5D-5L questionnaire has been included in the app as an 
optional questionnaire to complete monthly.
Patient support through reliable education
Patients are in need of information about their disease and 
treatment options. Their needs may vary depending on their 
phase in the disease journey but often the internet is their 
primary source of information (unpublished data). This infor-
mation might however be biased or unreliable. Consequently, 
EUFOREA has created a support platform for patients with upper 
airway disease with both online educational material as well 
as the educational platform available from mySinusitisCoach. 
EUFOREA key opinion leaders (KOLs) have collected frequently 
asked questions from their patients and answered them in short 
and easy to understand language. The questions and answers 
(Q&A) have been checked to match the health literacy of the 
average patient by a panel of primary care physicians for each 
country. The Q&A were classified into 5 topics (disease, diagno-
sis, treatment, surgery and quality of life) to facilitate the search 
for the patients.
Expected benefits for the different stakeholders
For the patient
This tool was developed in collaboration with patients to ensure 
acceptability and use over a prolonged period of time by a large 
group of patients. Feedback by the European patient organi-
zation (EFA) was obtained at different time points and the app 
was tested with patients during the development phase. Close 
monitoring of the patients’ rhinosinusitis symptoms, feedback 
about disease control and advice to contact their treating physi-
cian may lead to increased awareness of the patients about their 
disease, thereby contributing to better compliance with their 
therapy. The educational platform may lead to better knowledge 
about CRS and available treatment options allowing active parti-
cipation of patients in the management of their disease. 
For the healthcare professional
Longitudinal information about disease control and adherence 
to therapy will be available for the doctor. This information may 
help to decide upon the best treatment strategy and facilitate 
the patient-doctor interaction (28). The educational platform may 
aid the doctor in providing information on treatment options to 
the patient or allow referral to the platform which might be time 
saving. In addition this tool could identify those patients who 
are in need of more extensive medical or surgical treatment (29). 
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airway symptoms, sleep quality and work productivity.
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In the post-operative setting it may facilitate the follow-up of 
the surgical intervention as well as duration of effect.
For the scientific community
Currently, guidelines and care pathways are developed based 
on clinical studies that are performed in highly selected patient 
populations, for valid scientific reasons, however this does not 
validate the extrapolation of results achieved into the general 
population (30). mySinusitisCoach will provide real life data on 
the natural course of disease, socio-economic impact of CRS 
and outcomes of medical as well as surgical interventions. In 
addition, it allows the evaluation of the impact of CRS on lower 
References
1. Hastan D, Fokkens WJ, Bachert C, Newson 
RB, Bislimovska J, Bockelbrink A, et al. 
Chronic rhinosinusitis in Europe--an under-
estimated disease. A GA2LEN study. Allergy. 
2011;66(9):1216–23. 
2. Smith KA, Orlandi RR, Rudmik L. Cost of 
adult  chronic rhinosinusit is :  A sys-
temat ic  rev iew.  The Lar yngoscope. 
2015;125(7):1547–56. 
3. De Greve G, Hellings PW, Fokkens WJ, Pugin 
B, Steelant B, Seys SF. Endotype-driven 
treatment in chronic upper airway diseases. 
Clin Transl Allergy. 2017;7:22. 
4. Fokkens WJ, Lund VJ, Mullol J, Bachert C, 
Alobid I, Baroody F, et al. EPOS 2012: 
European position paper on rhinosinusi-
tis and nasal polyps 2012. A summary 
for otorhinolaryngologists. Rhinology. 
2012;50(1):1–12. 
5. van der Veen J, Seys SF, Timmermans M, 
Levie P, Jorissen M, Fokkens WJ, et al. Real-
life study showing uncontrolled rhinosinusi-
tis after sinus surgery in a tertiary referral 
centre. Allergy. 2017;72(2):282-290.
6. Snidvongs K, Heller GZ, Sacks R, Harvey 
RJ. Validity of European Position Paper 
on  R h inos inus i t i s  D i sease  Cont ro l 
Assessment and Modifications in Chronic 
Rhinosinusitis. Otolaryngol-Head Neck Surg. 
2014;150(3):479–86. 
7. Hellings PW, Fokkens WJ, Akdis C, Bachert C, 
Cingi C, Dietz de Loos D, et al. Uncontrolled 
allergic rhinitis and chronic rhinosinusi-
tis: where do we stand today? Allergy. 
2013;68(1):1–7. 
8. Hastan D, Fokkens WJ, Bachert C, Newson 
RB, Bislimovska J, Bockelbrink A, et al. 
Chronic rhinosinusitis in Europe--an under-
estimated disease. A GA2LEN study. Allergy. 
2011;66(9):1216–23. 
9. Hellings PW, Fokkens WJ, Bachert C, Akdis 
CA, Bieber T, Agache I, et al. Positioning 
the Principles of Precision Medicine in 
Care Pathways for Allergic Rhinitis and 
Chronic Rhinosinusitis - an EUFOREA-ARIA-
EPOS-AIRWAYS ICP statement. Allergy. 
2017;72(9):1297-1305. 
10. mHealth app developer economics study 
[Internet]. 2016. Available from: https://
research2guidance.com/r2g/r2g-mHealth-
App-Developer-Economics-2016.pdf
11. Bousquet J, Caimmi DP, Bedbrook A, Bewick 
M, Hellings PW, Devillier P, et al. Pilot study 
of mobile phone technology in allergic 
rhinitis in European countries: the MASK-
rhinitis study. Allergy. 2017;72(6):857–65. 
12. Bousquet J, Schünemann HJ, Hellings PW, 
Arnavielhe S, Bachert C, Bedbrook A, et al. 
MACVIA clinical decision algorithm in ado-
lescents and adults with allergic rhinitis. J 
Allergy Clin Immunol. 2016;138(2):367–374.
e2. 
13. Bousquet J, Caimmi DP, Bedbrook A, Bewick 
M, Hellings PW, Devillier P, et al. Pilot study 
of mobile phone technology in allergic 
rhinitis in European countries: the MASK-
rhinitis study. Allergy. 2017;72(6):857–65. 
14. Bousquet J,  Bewick M, Arnavielhe S, 
Mathieu-Dupas E, Murray R, Bedbrook A, 
et al. Work productivity in rhinitis using 
cell phones: The MASK pilot study. Allergy. 
2017;72(10):1475–84. 
15. Caimmi D, Baiz N, Tanno LK, Demoly P, 
Arnavielhe S, Murray R, et al. Validation 
of the MASK-rhinitis visual analogue 
scale on smartphone screens to assess 
allergic rhinitis control. Clin Exp Allergy. 
2017;42(12):1526-1533. 
16. Muraro A ,  Fok kens WJ,  Piet ik a inen 
S, Borrelli D, Agache I, Bousquet J, et al. 
European symposium on precision medi-
cine in allergy and airways diseases: report 
of the European Union parliament sym-
posium (October 14, 2015). Rhinology. 
2015;53(4):303–7. 
17. Muraro A, Lemanske RF, Hellings PW, 
Akdis CA, Bieber T,  Casale TB, et al. 
Precision medicine in patients with aller-
gic diseases: Airway diseases and atopic 
dermatitis-PRACTALL document of the 
European Academy of Allergy and Clinical 
Immunology and the American Academy 
of Allergy, Asthma & Immunology. J Allergy 
Clin Immunol. 2016;137(5):1347–58. 
18. Hellings PW, Akdis CA, Bachert C, Bousquet 
J, Pugin B, Adriaensen G, et al. EUFOREA 
Rhinology Research Forum 2016: report 
of the brainstorming sessions on needs 
and priorities in rhinitis and rhinosinusitis. 
Rhinology. 2017;55(3):202–10. 
19. Philpott C, Erskine S, Smith R, Hopkins 
C, Kara N, Farboud A, et al. Current use 
of baseline medical treatment in chron-
ic rhinosinusitis: Data from the National 
Chronic Rhinosinusitis Epidemiology Study 
(CRES). Clin Otolaryngol. 2017; doi: 10.1111/
coa.13012. [Epub ahead of print]
20. Rudmik L, Xu Y, Liu M, Bird C, Kukec E, Quan 
H. Utilization Patterns of Topical Intranasal 
Steroid Therapy for Chronic Rhinosinusitis: 
A Canadian Population-Based Analysis. 
JAMA Otolaryngol-- Head Neck Surg. 
2016;142(11):1056–62. 
21. Nabi S, Rotenberg BW, Vukin I, Payton 
K, Bureau Y. Nasal spray adherence after 
sinus surgery: problems and predictors. 
J Otolaryngol - Head Neck Surg. 2012;41 
Suppl 1:S49-55. 
22. Bousquet J, Schunemann HJ, Fonseca J, 
Samolinski B, Bachert C, Canonica GW, et 
al. MACVIA-ARIA Sentinel NetworK for aller-
gic rhinitis (MASK-rhinitis): the new gen-
eration guideline implementation. Allergy. 
2015;70(11):1372–92. 
23. Piccirillo JF, Merritt MG, Richards ML. 
Psychometr ic  and cl inimetr ic  val id-
ity of the 20-Item Sino-Nasal Outcome Test 
(SNOT-20). Otolaryngol--Head Neck Surg. 
2002;126(1):41–7. 
24. Hopkins C, Gillett S, Slack R, Lund VJ, 
Browne JP. Psychometric validity of the 
22-item Sinonasal Outcome Test. Clin 
Otolaryngol. 2009;34(5):447–54. 
25. Dietz de Loos DAE, Segboer CL, Gevorgyan 
A, Fokkens WJ. Disease-specific quality-of-
life questionnaires in rhinitis and rhinosi-
nusitis: review and evaluation. Curr Allergy 
Asthma Rep. 2013;13(2):162–70. 
26. Rudmik L, Soler ZM, Hopkins C, Schlosser 
RJ, Peters A, White AA, et al. Defining appro-
priateness criteria for endoscopic sinus sur-
gery during management of uncompli-
cated adult chronic rhinosinusitis: a RAND/
UCLA appropriateness study. Rhinology. 
2016;54(2):117–28. 
27. Herdman M, Gudex C, Lloyd A, Janssen M, 
Kind P, Parkin D, et al. Development and 
preliminary testing of the new five-level 
version of EQ-5D (EQ-5D-5L). Qual Life Res. 
215
Seys et al.
Sven Seys
EUFOREA
Brand Whitlocklaan 132
1300 Brussels
Belgium
E-mail: sven.seys@euforea.eu
2011;20(10):1727–36. 
28. Gamble J, Stevenson M, Heaney LG. A study 
of a multi-level intervention to improve 
non-adherence in difficult to control asth-
ma. Respir Med. 2011;105(9):1308–15. 
29. Rudmik L, Soler ZM, Hopkins C. Using 
postoperative SNOT-22 to help predict 
the probability of revision sinus surgery. 
Rhinology. 2016;54(2):111–6. 
30. Costa DJ, Amouyal M, Lambert P, Ryan D, 
Schünemann HJ, Daures JP, et al. How rep-
resentative are clinical study patients with 
allergic rhinitis in primary care? J Allergy 
Clin Immunol. 2011;127(4):920–926.e1.
